Targeted NGS revealed that CHEK2 was the second most frequently altered gene (following heterozygous MUTYH) in the Ambry Genetics ColoNext panel with germline CHEK2 mutations found in 8/586 colon cancer patients [238]. This evidence concerns the gene CHEK2 and malignant colon neoplasm.